Auranofin

SIGMA/A6733 - ≥98% (HPLC)

Synonym: 1-Thio-β-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate; 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium; SKF 39162

CAS Number: 34031-32-8
Empirical Formula (Hill Notation): C₂₀H₃₄AuO₉PS
Molecular Weight: 678.48
EC Number: 251-801-9
MDL Number: MFCD00080759
Linear Formula: C₂₀H₃₄AuO₉PS
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-A6733-10MG	10 mg	$119.00 1/EA	Add To Favorites
45-A6733-50MG	50 mg	$472.00 1/EA	Add To Favorites

This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: A6733-10MG

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
form	powder
InChI	1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1/t10-,11-,12+,13-,14+;;/m1../s1
InChI key	AUJRCFUBUPVWSZ-XTZHGVARSA-M
originator	Prometheus
Quality Level	100
SMILES string	CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
solubility	DMSO: ≥5 mg/mL
storage temp.	room temp

Application:	Auranofin inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin also inhibits 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5 and selenoenzyme thioredoxin reductase (TrxR) which is involved in the defense against oxidative stress. Auranofin is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.
Biochem/physiol Actions:	Auranofin inhibits various leukocyte activation pathways at multiple sites and is a disease-modifying antirheumatic drug (DMARD).
Biochem/physiol Actions:	Auranofin inhibits various leukocyte activation pathways at multiple sites. Auranofin inhibits the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. The compound also inhibits 5-lipoxygenase in human neutrophils. Auranofin is a disease-modifying antirheumatic drug (DMARD). The compound is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress. Auranofin is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase. Auranofin inhibits IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5.
Features and Benefits:	This compound was developed by Prometheus . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here .
Packaging:	10, 50 mg in glass bottle

Symbol	GHS06,GHS08
Signal word	Danger
Hazard statements	H301 - H361
Precautionary statements	P201 - P202 - P264 - P270 - P280 - P301 + P310
Hazard Codes	Xn
Risk Statements	63-22
Safety Statements	36/37
RIDADR	UN 2811 6.1 / PGIII
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
Storage Temp.	room temp
UNSPSC	51111800

To Order From a Quote